Results 91 to 100 of about 3,654 (190)

Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir

, 2018
BACKGROUND & AIMS: Chronic infection with hepatitis C virus (HCV) has many hepatic and extrahepatic manifestations, measured by patient-reported outcomes (PROs).
Younossi, Issah, Reddy, K R, Bourliere, Marc, Gordon, Stuart, Jacobson, Ira, Stepanova, Maria, Flamm, Steven, Mann, Michael P, Kowdley, Kris V, Reddy, K Rajender, Gordon, Stuart C, Cooper, Curtis, Younossi, Zobair M, Kowdley, Kris, Hunt, Sharon, Zeuzem, Stefan   +15 more
core  

Hur effektiv och säker är kombinationen av sofosbuvir och velpatasvir mot kronisk hepatit C-infektion

, 2017
Around 130-150 million people are chronically infected with hepatitis C-virus today. Personal suffering and great societal costs aside, this also causes around 400 000 deaths every year due to complications.
Rydén, Björn
core   +1 more source

Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir

, 2016
During a phase 3 study evaluating the combination of sofosbuvir-velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV ...
Svarovskaia, Evguenia, Moreno, Christophe, Schreiber, Jonas, John McNally, Krishna Chodavarapu, McNally, John, Christophe Moreno, Chodavarapu, Krishna, Evguenia Svarovskaia, Jonas Schreiber   +9 more
core   +1 more source

Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden

, 2019
Background: In both Russia and Sweden, the dominant hepatitis C virus (HCV) is genotype 1, but around one-third of patients have genotype 3 infection. For such countries, HCV genotype testing is recommended prior to therapy.
Abdurakhmanov, D., Brainard, D. M., Gankina, N., Kozhevnikova, G., Lu, S., Zhuravel, S., McNally, J., Lagging, Martin,, Chulanov, V., Romanova, S., Weiland, O., Svarovskaia, E. S., Zhdanov, K., Hyland, R. H., Ivashkin, V., Morozov, V., Isakov, V., Burnevich, E., Nurmukhametova, E., Bakulin, I.   +19 more
core   +1 more source

Direct-Acting Antiviral Agents in Prevention of Maternal–Fetal Transmission of Hepatitis C Virus in Pregnancy

Pathogens
Prior to the Food and Drug Administration approval of ledipaspavir/sofosbuvir (Harvoni®) in 2014, the treatment of hepatitis C was interferon plus or minus ribavirin.
Christopher Hartley, Trung Van, Wikrom Karnsakul   +2 more
doaj   +1 more source

Stability indicating RP-HPLC method development and validation for the simultaneous determination of Sofosbuvir and Velpatasvir in tablet dosage forms

, 2017
Stability indicating RP-HPLC method was developed for the simultaneous quantitation of Sofosbuvir and Velpatasvir in its pharmaceutical dosage form and validated.
Ganapaty, S., Bandla, Jahnavi, Jahnavi Bandla, S. Ganapaty   +3 more
core   +1 more source

Enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis C drug velpatasvir in pharmaceutical tablets and body fluids

, 2018
Highly sensitive and selective solid phase extraction method combined with cloud point extraction strategy was developed for analysis of velpatasvir in its pharmaceutical tablets and biological fluids.
Mohamed M. El-Wekil, Ramadan Ali, Adel A. Marzouk, Hassan Refat H. Ali   +3 more
core   +1 more source

An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences

Pathogens
Direct-acting antivirals (DAAs) revolutionized the therapeutics of chronic hepatitis C. The emergence and transmission of HCV variants with resistance-associated substitutions (RASs) can undermine HCV treatment.
Roaa Khalil, Kholoud Al-Mahzoum, Muna Barakat, Malik Sallam   +3 more
doaj   +1 more source

Issue Information

The Kaohsiung Journal of Medical Sciences, Volume 41, Issue 11, November 2025.
wiley   +1 more source

Velpatasvir [PDF]

, 2020
openaire   +1 more source